Rasmussen Sten, Aboo Christopher, Skallerup Jacob, Stensballe Allan
Department of Orthopedic Surgery, Sport and Arthroscopy, Aalborg University Hospital, Denmark.
Department of Clinical Medicine, Aalborg University, Denmark.
Osteoarthr Cartil Open. 2024 Aug 31;6(4):100514. doi: 10.1016/j.ocarto.2024.100514. eCollection 2024 Dec.
In a previous pilot study, we have shown that intraarticular gold micro-particles can reduce knee osteoarthritis (KOA) pain at two years follow-up. Proteomic changes in serum and synovial fluid within eight weeks were associated with multiple inflammatory and immunological processes. The relation between the different biomarkers and the outcome measures is not known. We hypothesized that improvement in pain and function were associated with specific groups of biomarkers. We present the integrative analyses between proteomic biomarkers and outcomes.
A cohort of 30 patients, with moderate KOA, were included. Using the patients' synovial fluid as the carrier, 20 mg gold microparticles were injected intraarticularly. Clinical outcome measures at inclusion, 8 weeks, and 2 years, were the PainDetect questionnaire, WOMAC pain, stiffness, and function. In addition, Quantitative Sensory Testing, Pain Pressure Threshold, Temporal Summation, Conditioned Pain Modulation, and pain diary were assessed at inclusion and after 8 weeks. Proteomic analysis was performed on SF and blood samples before and after 8 weeks of treatment.
Linear combinations of serum or synovial biomarkers changed significantly alongside the effect measures and PainDetect scores following gold micro-particle treatment. Of particular interest was identifying multiple members of a molecular complex that is suggestive of neural tissue regeneration and modulation following gold micro-particle treatment.
Gold microparticles are a possible future option for the treatment of knee osteoarthritis. The treatment triggers putative regenerative and inflammation-modulating molecular mechanisms.
在之前的一项初步研究中，我们已经表明，关节内注射金微粒在两年的随访中可减轻膝关节骨关节炎（KOA）疼痛。八周内血清和滑液中的蛋白质组变化与多种炎症和免疫过程相关。不同生物标志物与结局指标之间的关系尚不清楚。我们假设疼痛和功能的改善与特定的生物标志物组相关。我们展示了蛋白质组生物标志物与结局之间的综合分析。
纳入30例中度KOA患者。以患者的滑液为载体，关节内注射20mg金微粒。纳入时、8周和2年时的临床结局指标为疼痛检测问卷、WOMAC疼痛、僵硬和功能。此外，在纳入时和8周后评估定量感觉测试、疼痛压力阈值、时间总和、条件性疼痛调制和疼痛日记。在治疗8周前后对滑液和血液样本进行蛋白质组分析。
金微粒治疗后，血清或滑膜生物标志物的线性组合随效应指标和疼痛检测评分显著变化。特别值得关注的是，在金微粒治疗后，鉴定出一个分子复合体的多个成员，提示神经组织再生和调节。
金微粒可能是未来治疗膝关节骨关节炎的一种选择。该治疗触发了假定的再生和炎症调节分子机制。
